University of Saskatchewan<\/a>, is leading the research that will better identify the protein, or biomarkers, on therapy-resistant cells, like HER2.<\/p>\n\u201cWhen a patient goes to a clinic, they would get injected with a radiopharmaceutical that would more accurately tell which protein is responsible for that cancer and that would allow the physician to more accurately determine treatment to a particular drug rather than a one-size-fits-all method,\u201d he said.<\/p>\n
The research is still in the animal-testing phase. Humphrey estimates it will take a \u201cfew years\u201d before it goes to Health Canada for approval.<\/p>\n
\u201cIt\u2019s going to be revolutionary. It will save a lot of costs. If a patient goes to a clinic and is treated with a $70,000 drug and they don\u2019t respond to drug, that\u2019s a loss of $70,000.\u201d<\/p>\n
Not only will the imaging agent help to determine which drug therapy should be used, but it will also be able to monitor how patients respond to that\u00a0therapy.<\/p>\n
![\"Editorial](\"http:\/\/talknuclear.ca\/wp-content\/uploads\/2015\/04\/Editorial-Breast-cancer-300x221.jpg\")
Innovative nuclear research may soon be able to tell in advance whether breast-cancer patients require specific hormone treatments \u2013 a breakthrough that could save a lot of time and money.<\/p>\n